Non-clear cell advanced kidney cancer: Is there a gold standard?

Anti-Cancer Drugs

Volumn 22, Issue SUPPL. 1, 2011, Pages

  Sánchez, Pedro ^a,c   Calvo, Emiliano ^a,b   Durán, Ignacio ^a,b  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b START   (Spain)

^c INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

Chromophobe; collecting duct; non clear cell; papillary; treatment

Indexed keywords

ALPHA INTERFERON; BANOXANTRONE; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DNA TOPOISOMERASE; ELONGIN B; ELONGIN C; ERLOTINIB; EVEROLIMUS; FORETINIB; FUMARATE HYDRATASE; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

BIRT HOGG DUBE SYNDROME; CHROMOSOME; CITRIC ACID CYCLE; DISEASE CLASSIFICATION; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LEIOMYOMATOSIS; LUNG CYST; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU DISEASE;

EID: 78650839264     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000390767.85658.83     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Cohen HT, McGovern FJ. Renal cell carcinoma. N Engl J Med 2005; 353:2477-2490.
3. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183:131-133.
4. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol 2003; 170:2163-2172.
5. Pack SD, Zbar B, Pak E, Ault DO, Humphrey JS, Pham T, et al. Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in-situ hybridization. Cancer Res 1999; 59:5560-5564.
6. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour-suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90.
7. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008; 14:4726-4734.
8. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2:pe24.
9. Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998; 58:1719-1722.
10. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, et al. Germ line BHD mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 2005; 76:1023-1033.
11. Baba M, Hong SB, Sharma N,Warren MB, Nickerson ML, Iwamatsu A, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006; 103:15552-15557.
12. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germ line mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406-410.
13. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8:143-153.
14. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor-1-a stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009; 29:4080-4090.
15. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009; 7:618-630.
16. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon-a, or both for advanced renal cell carcinoma. N Engl J Med 2007; 356:2271-2281.
17. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26:127-131.
18. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27:235-241.
19. Stadler WM, Ernstoff MS, Curti B, Figlin A, Pendergrass K, Srinivas S, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). Journal of Clinical Oncology 2007; 25:5036.
20. Plimack E, Jonasch E, Bekele B, Qiao W, Ng CS, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (NCC-RCC): a phase II study. J Clin Oncol 2010; 28:4604.
21. Gore ME, Oudard S, Bjarnason G, Porta C, Castellano D, Szczylik C, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007; 20:5010.
22. Pan C, Lara N, Mack PC, Hussey M, Nagle R, Dutcher JP, et al. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (PRCC): Final results from Southwest Oncology Group study 0317. J Clin Oncol 2008; 20:5051.
23. Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology 2007; 73:204-209.
24. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010; 116:1272-1280.
25. Escudier B, Droz JP, Rolland F, Terrier-Lacombe MJ, Gravis G, Beuzeboc P, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. J Urol 2002; 168:959-961.
26. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101:1545-1551.
27. Chowdhury S, Choueiri TK. Recent advances in the systemic treatment of metastatic papillary renal cancer. Expert Rev Anticancer Ther 2009; 9:373-379.
28. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 2002; 20:2376-2381.
29. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006; 107:2617-2621.
30. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res 2005; 65:5628-5637.
31. Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res 2000; 6:1518-1523.
32. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69:8009-8016.
33. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009; 8:626-635.
34. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 2008; 32:1822-1834.
35. Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, et al. Genomic expression and single nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 2010; 10:196.
36. Schuetz AN, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, Hornsby CD, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 2005; 7:206-218.
37. Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C. Chromophobe renal cell cancer: review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res 2009; 28:134.
38. Wright JL, Risk MC, Hotaling J, Lin DW. Effect of collecting duct histology on renal cell cancer outcome. J Urol 2009; 182:2595-2599.
39. Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study. J Urol 2007; 177:1698-1702.
40. Orsola A, Trias I, Raventos CX, Español I, Cecchini L, Orsola I. Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology 2005; 65:49-54.
41. Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 2009; 32:44-46.
42. Wu ZS, Lee JH, Kwon JA, Kim SH, Han SH, An JS, et al. Genetic alterations and chemosensitivity profile in newly established human renal collecting duct carcinoma cell lines. BJU Int 2009; 103:1721-1728.
43. Papadopoulos KP, Goel S, Beeram M,Wong A, Desai K, Haigentz M, et al. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies. Clin Cancer Res 2008; 14:7110-7115.
44. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49:798-805.
45. Margulis V, McDonald M, Tamboli P, Swanson DA,Wood CG. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 2009; 181:2044-2051.
46. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25:275-284.